{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:05:31Z","timestamp":1784786731577,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder causing a variety of motor and non-motor symptoms. To date, no disease modifying treatment exists, and diagnosis is based on the manifestation of the clinical motor symptoms, which occurs when the neurodegenerative process is already advanced. Studies designed to find diagnostic\/prognostic biomarkers and pathophysiological pathways involved in disease onset\/progression are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To describe the study protocol of the Vall d\u2019Hebron Initiative for Parkinson (VHIP) Cohort, a prospective and longitudinal observational cohort study aimed at deeply phenotyping\n                      <jats:italic>de novo<\/jats:italic>\n                      PD patients, including carriers of PD-linked mutations. We anticipate this initiative will contribute to identifying biomarkers for PD risk, diagnosis, and prognosis, as well as to stratify disease subtypes and increase our understanding of pathophysiology at early disease stages.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/Design<\/jats:title>\n                    <jats:p>\n                      Subjects are prospectively recruited by movement disorder specialists at the Vall d\u2019Hebron University Hospital (VHUH). To date, the study cohort includes 174 subjects\u2014consisting of 117 patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      Parkinson\u2019s disease, 17 individuals with REM sleep behavior disorder (RBD), and 33 healthy controls\u2014and recruitment is still ongoing. After informed consent, subjects are evaluated in detail to primarily assess objectives within four major domains of PD: motor, cognitive-affective, autonomic function, and vision. This includes first an extensive clinical evaluation (i) recording demographic, personal history, lifestyle, and dietary habits and (ii) performing clinical scales covering motor and non-motor symptoms. Second, data from autonomic function and visual function tests, together with neuroimaging data, are acquired. And finally, a wide range of biospecimens are collected for biochemical and molecular assessments including the genotyping of all participants. Participants receive follow-up assessments at 2.5 and 5-year intervals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/Discussion<\/jats:title>\n                    <jats:p>\n                      VHIP is the first study to establish a Spanish cohort combining clinical, imaging, biochemical and molecular data over time in\n                      <jats:italic>de novo<\/jats:italic>\n                      patients, including PD-linked mutation carriers. VHIP provides a unique opportunity to link pre-diagnosis disturbances to PD development, as well as to identify risk, diagnosis, and prognosis biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/vhir.vallhebron.com\/es\/investigacion\/proyecto-vall-dhebron-iniciativa-para-el-parkinson-vhip<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1858685","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:37:50Z","timestamp":1784785070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Vall d\u2019Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal, and observational study enrolling de novo Parkinson\u2019s disease patients for biomarker identification and validation"],"prefix":"10.3389","volume":"18","author":[{"given":"Daniela","family":"Samaniego","sequence":"first","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Department of Medicine, Autonomous University of Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Enr\u00edquez-Calzada","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Department of Medicine, Autonomous University of Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Domingo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Armengol","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Camprod\u00f3n","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Department of Medicine, Autonomous University of Barcelona","place":["Barcelona, Spain"]},{"name":"Rare and Metabolic Diseases Unit, University Hospital Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Melgarejo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Arr\u00fae-Gonzalo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Miret-Milian","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Neurology Unit, University Hospital Vall d\u2019Hebron","place":["Barcelona, Spain"]},{"name":"Innovative Therapies in Pediatric Neurology Research Group, Vall d\u2019Hebron Research Institute (VHIR)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Belmonte","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Neurology Unit, University Hospital Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lucas-Del-Pozo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Xicoy","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L\u00f3pez","family":"Carrasco","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Riera","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Pradas","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Castillo-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Montpey\u00f3","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montpey\u00f3","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Zapata","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, University Hospital Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Vila","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona","place":["Barcelona, Spain"]},{"name":"Catalan Institution for Research and Advanced Studies (ICREA)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00ednez-Vicente","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Laguna","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hern\u00e1ndez-Vara","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Research Group, Vall d\u2019Hebron Research Institute (VHIR), Instituto de Investigaci\u00f3n Sanitaria Acreditado Hospital Universitario Vall d\u2019Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)","place":["Barcelona, Spain"]},{"name":"Neurology Unit, University Hospital Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref9001","doi-asserted-by":"publisher","first-page":"14820","DOI":"10.1038\/s41598-021-94345-8","article-title":"Temporal trajectory of biofluid markers in Parkinson\u2019s disease","volume":"11","author":"Baek","year":"2021","journal-title":"Sci Rep"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.parkreldis.2012.09.007","article-title":"Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease","volume":"19","author":"Barrett","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S1474-4422(08)70239-4","article-title":"Transcranial sonography settings for the assessment of the substantia nigra","volume":"38","author":"Berg","year":"2012","journal-title":"Ultrasound Med. Biol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12883-019-1394-3","article-title":"The personalized Parkinson project: examining disease progression through broad biomarkers in early Parkinson\u2019s disease","volume":"19","author":"Bloem","year":"2019","journal-title":"BMC Neurol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12883-020-01811-3","article-title":"Study protocol of the DUtch PARkinson cohort (DUPARC): a prospective, observational study of de novo Parkinson\u2019s disease patients for the identification and validation of biomarkers for Parkinson\u2019s disease subtypes, progression and pathophysiology","volume":"20","author":"Boertien","year":"2020","journal-title":"BMC Neurol."},{"key":"ref9002","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02918-y","article-title":"Vienna, Austria: Springer-Verlag","author":"Campagnolo","year":"2025"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2014a call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1288\/00005537-198402000-00004","article-title":"University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic","volume":"94","author":"Doty","year":"1984","journal-title":"Laryngoscope"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin. Auton. Res."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/01.HYP.0000188052.69549.e4","article-title":"Cardiac sympathetic denervation precedes nigrostriatal denervation in Parkinson disease","volume":"17","author":"Goldstein","year":"2005","journal-title":"Clin. Auton. Res."},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1001\/archophthalmol.2009.106","volume-title":"Inner Retinal Layer Thinning in Parkinson Disease","author":"Hajee","year":"2009"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1126\/science.1957169","article-title":"Optical coherence tomography","volume":"254","author":"Huang","year":"1991","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson\u2019s disease questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score","volume":"26","author":"Jenkinson","year":"1997","journal-title":"Age Ageing"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1212\/WNL.56.7.980","article-title":"Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure","volume":"56","author":"Kaufmann","year":"2001","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI)\u2014establishing a longitudinal cohort and biorepository","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0165-1781(91)90040-V","article-title":"Reliability and validity of the apathy evaluation scale","volume":"38","author":"Marin","year":"1991","journal-title":"Psychiatry Res."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL is increased in synucleinopathies and correlates with disease severity","volume":"6","author":"Marques","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-023-00503-2","article-title":"Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson\u2019s disease","volume":"9","author":"Mart\u00ednez","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/mds.28206","article-title":"Validation of a multi-marker approach for PD diagnosis using CSF biomarkers","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov. Disord."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref33","volume-title":"Estudio del Sistema Nervioso Aut\u00f3nomo en la Enfermedad de Parkinson y Otras Alfasinucleinopat\u00edas","author":"Navarro-Otano","year":"2014"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.parkreldis.2012.01.009","article-title":"[123]I-MIBG myocardial scintigraphy in Parkinson\u2019s disease and related diseases","volume":"10","author":"Orimo","year":"2012","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1212\/CON.0000000000000816","article-title":"Orthostatic hypotension in Parkinson disease","volume":"26","author":"Palma","year":"2020","journal-title":"Continuum (Minneap Minn)."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2016.02.014","article-title":"Rome IV diagnostic questionnaires and tables for investigators and clinicians","volume":"150","author":"Palsson","year":"2016","journal-title":"Gastroenterology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ene.13573","article-title":"Neuromelanin sensitive MsRI in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"53","author":"Prasad","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000715","article-title":"GBA1-associated parkinsonism: new insights and therapeutic opportunities","volume":"32","author":"Ryan","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12883-016-0548-9","article-title":"COPPADIS-2015 (COhort of Patients with Parkinson\u2019s DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson\u2019s disease progression","volume":"16","author":"Santos-Garcia","year":"2016","journal-title":"BMC Neurol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/01.wnr.0000227984.84927.a7","article-title":"Neuromelanin-sensitive MRI of the substantia nigra and locus ceruleus: a review of recent findings","volume":"63","author":"Sasaki","year":"2006","journal-title":"Neuroradiology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov. Disord."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3945\/jn.110.135566","article-title":"A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women","volume":"141","author":"Schr\u00f6der","year":"2011","journal-title":"J. Nutr."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1474-4422(19)30319-9","article-title":"Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA carriers in the Parkinson\u2019s progression markers initiative (PPMI)","volume":"10","author":"Simuni","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale","volume":"167","author":"Snaith","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"ref50","year":"2025"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"553635","DOI":"10.3389\/fnagi.2020.553635","article-title":"Phenotype-agnostic molecular subtyping of neurodegenerative disorders: the Cincinnati cohort biomarker program (CCBP)","volume":"12","author":"Sturchio","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-018-0047-3","article-title":"Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson\u2019s disease","volume":"4","author":"Sulzer","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Teunissen","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson\u2019s disease sleep scale\u2014validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"710572","DOI":"10.3389\/fneur.2021.710572","article-title":"LIPAD (LRRK2\/Luebeck international Parkinson\u2019s disease) study protocol: deep phenotyping of an international genetic cohort","volume":"12","author":"Usnich","year":"2021","journal-title":"Front. Neurol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","article-title":"Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT","volume":"19","author":"Visser","year":"2004","journal-title":"Mov. Disord."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","article-title":"Prevalence and incidence of Parkinson\u2019s disease in Europe","volume":"15","author":"Von Campenhausen","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","article-title":"Performance of a shortened scale for assessment of positive symptoms for Parkinson\u2019s disease psychosis","volume":"19","author":"Voss","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fneur.2019.00053","article-title":"The investigation of the autonomic nervous system","volume":"266","author":"Ziemssen","year":"2019","journal-title":"J. Neurol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.21037\/qims-20-460","article-title":"Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson\u2019s disease","volume":"10","author":"Zou","year":"2023","journal-title":"Quant. Imaging Med. Surg."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1858685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:37:51Z","timestamp":1784785071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1858685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":56,"alternative-id":["10.3389\/fnagi.2026.1858685"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1858685","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1858685"}}